LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases

Journal of Vaccines and Vaccination

Volumn 3, Issue 5, 2012, Pages

  Zimmerman, Daniel H ^a   Steiner III, Harold ^a   Carmabula, Roy ^a   Talor, Eyal ^a   Rosenthal, Ken S ^b  

^a CEL SCI Corporation   (United States)

^b Northeast Ohio Medical University   (United States)

Author keywords

Antiviral vaccines; Autoimmunity; Cytokines; Dendritic cell; Immune response; Mode of action; Peptide; T cells; Vaccines

Indexed keywords

EID: 84879644138     PISSN: None     EISSN: 21577560     Source Type: Journal    
DOI: 10.4172/2157-7560.1000149     Document Type: Article

References (65)

1. Rosenthal KS (2005) Immune peptide enhancement of peptide based vaccines. Front Biosci 10: 478-482.
2. Zimmerman D, Bergmann K, Rosenthal K and Elliott D (1996) A new approach to T-cell activation: natural and synthetic conjugates capable of activating T cells. Vaccine research. Liebert 5: 91-102.
3. Zimmerman DH, Morris S, Rouse D, Worthington K, Elliott D, et al. (1996) Immunization with peptide heterconjugates primes a t helper cell type 1-associated antibody (IgG2a) response that recognizes the native epitope on the 38-kDA protein of Mycobacterium tuberculosis. Vaccine research. Liebert 5: 103-118.
4. Taylor PR, Paustian CC, Koski GK, Zimmerman DH and Rosenthal KS (2010) Maturation of dendritic cell precursors into IL12-producing DCs by J-LEAPS immunogens. Cellular immunology 262: 1-5.
5. Taylor PR, Koski GK, Paustian CC, Bailey E, Cohen PA, et al. (2010) J-LEAPS vaccines initiate murine Th1 responses by activating dendritic cells. Vaccine 28: 5533-5542.
6. Goel N, Rong Q, Zimmerman D, Rosenthal KS (2003) A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection. Vaccine 21: 4410-4420.
7. Goel N, Zimmerman DH and Rosenthal KS (2005) Ligand Epitope Antigen Presentation system vaccines against herpes simplex virus. Frontiers in Bioscience 10: 966-974.
8. Boonnak K, Vogel L, Orandle M, Zimmerman D, Talor E, et al. (2012) Targeting dendritic cells: a novel strategy to treat influenza virus infection. Manuscript submitted.
9. Zimmerman DH, Taylor P, Bendele A, Carambula R, Duzant Y, et al. (2010) CEL-2000: A therapeutic vaccine for rheumatoid arthritis arrests disease development and alters serum cytokine/chemokine patterns in the bovine collagen type II induced arthritis in the DBA mouse model. International immunopharmacology 10: 412-421.
10. Cihakova D, Barin JG, Baldeviano GC, Kimura M, Talor MV, et al. (2008) L.E.A.P.S. heteroconjugate is able to prevent and treat experimental autoimmune myocarditis by altering trafficking of autoaggressive cells to the heart. Int Immunopharmacol 8: 624-633.
11. Rosenthal KS, Taylor P, Zimmerman DH (2012) J-LEAPS peptide and LEAPS dendritic cell vaccines. Microb Biotechnol 5: 203-213.
12. Parham P, Androlewicz MJ, Holmes NJ, Rothenberg BE (1983) Arginine 45 is a major part of the antigenic determinant of human beta 2-microglobulin recognized by mouse monoclonal antibody BBM.1. J Biol Chem 258: 6179-6186.
13. Konig R, Huang LY, Germain RN (1992) MHC class II interaction with CD4 mediated by a region analogous to the MHC class I binding site for CD8. Nature 356: 796-798.
14. Cammarota G, Scheirle A, Takacs B, Doran DM, Knorr R, et al. (1992) Identification of a CD4 binding site on the beta 2 domain of HLA-DR molecules. Nature 356: 799-801.
15. Pisarev VM, Parajuli P, Mosley RL, Chavez J, Zimmerman D, et al. (2002) Flt3 ligand and conjugation to IL-1beta peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine. Vaccine 20: 2358-2368.
16. Walton C, Jube S, Schorlemmer A, Patek P, Zimmerman D, et al. (2010) Ex vivo stimulation assay for T-cell responses for tuberculosis using LEAPS-peptide heteroconjugates. Curr Trends in Microbiol 6: 1-12.
17. Zimmerman DH, Lloyd JP, Heisey D, Winship MD, Siwek M, et al. (2001) Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1(SF2) p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain. Vaccine 19: 4750-4759.
18. Zimmerman DH, Rosenthal KS (2005) The L.E.A.P.S. approach to vaccine development. Front Biosci 10: 790-798.
19. Rosenthal KS, Mao H, Horne WI, Wright C, Zimmerman D (1999) Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1. Vaccine 17: 535-542.
20. Charoenvit Y, Goel N, Whelan M, Rosenthal KS, Zimmerman DH (2004) CEL-1000--a peptide with adjuvant activity for Th1 immune responses. Vaccine 22: 2368-2373.
21. Cihakova D, Barin JG, Afanasyeva M, Kimura M, Fairweather D, et al. (2008) Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am J Pathol 172: 1195-1208.
22. Donermeyer DL, Beisel KW, Allen PM, Smith SC (1995) Myocarditis-inducing epitope of myosin binds constitutively and stably to I-Ak on antigen-presenting cells in the heart. J Exp Med 182: 1291-1300.
23. Göser S, Ottl R, Brodner A, Dengler TJ, Torzewski J, et al. (2005) Critical role for monocyte chemoattractant protein-1 and macrophage inflammatory protein-1alpha in induction of experimental autoimmune myocarditis and effective anti-monocyte chemoattractant protein-1 gene therapy. Circulation 112: 3400-3407.
24. Pedotti R, Sanna M, Tsai M, DeVoss J, Steinman L, et al. (2003) Severe anaphylactic reactions to glutamic acid decarboxylase (GAD) self peptides in NOD mice that spontaneously develop autoimmune type 1 diabetes mellitus. BMC Immunol 4: 2.
25. Pedotti R, DeVoss JJ, Youssef S, Mitchell D, Wedemeyer J, et al. (2003) Multiple elements of the allergic arm of the immune response modulate autoimmune demyelination. Proc Natl Acad Sci U S A 100: 1867-1872.
26. Leech MD, Chung CY, Culshaw A, Anderton SM (2007) Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis. Eur J Immunol 37: 3576-3581.
27. Liu E, Yu L, Moriyama H, Eisenbarth GS (2004) Animal models of insulin-dependent diabetes. Methods Mol Med 102: 195-212.
28. Liu E, Moriyama H, Abiru N, Paronen J, Devendra D, et al. (2004) Preventing peptide-induced anaphylaxis: addition of C-terminal amino acids to produce a neutral isoelectric point. J Allergy Clin Immunol 114: 607-613.
29. Liu E, Moriyama H, Abiru N, Miao D, Yu L, et al. (2002) Anti-peptide autoantibodies and fatal anaphylaxis in NOD mice in response to insulin self-peptides B:9-23 and B:13-23. J Clin Invest 110: 1021-1027.
30. Myers LK, Terato K, Seyer JM, Stuart JM, Kang AH (1992) Characterization of a tolerogenic T cell epitope of type II collagen and its relevance to collagen-induced arthritis. J Immunol 149: 1439-1443.
31. Honda A, Ametani A, Matsumoto T, Iwaya A, Kano H, et al. (2004) Vaccination with an immunodominant peptide of bovine type II collagen induces an anti-TCR response, and modulates the onset and severity of collagen-induced arthritis. Int Immunol 16: 737-745.
32. Kannan K, Ortmann RA, Kimpel D (2005) Animal models of rheumatoid arthritis and their relevance to human disease. Pathophysiology 12: 167-181.
33. Brand DD (2005) Rodent models of rheumatoid arthritis. Comp Med 55: 114-122.
34. Bevaart L, Vervoordeldonk MJ, Tak PP (2010) Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? Arthritis Rheum 62: 2192-2205.
35. Nadelman CM, Newcomer VD (2000) Herpes simplex virus infections. New treatment approaches make early diagnosis even more important. Postgrad Med 107: 189-195, 199-200.
36. Whitley R and Gnann J (1993) The epidemiology and clinical manifestations of herpes simplex virus infections. The human herpes viruses. Raven Press, New York, pp 69-105.
37. Gilman SC, Docherty JJ, Clarke A, Rawls WE (1980) Reaction patterns of herpes simplex virus type 1 and type 2 proteins with sera of patients with uterine cervical carcinoma and matched controls. Cancer Res 40: 4640-4647.
38. Docherty JJ, Lohse MA, Dellaria MF, Naugle FP, Mason CW, et al. (1984) Incidence of herpes simplex virus types 1 and 2 in penile lesions of college men. J Med Virol 13: 163-170.
39. Docherty JJ, Trimble JJ, Roman SR, Faulkner SC, Naugle FP, et al. (1985) Lack of oral HSV-2 in a college student population. J Med Virol 16: 283-287.
40. Zimmerman DH, Mundon FK, Croson SE, Henchal LS, Docherty JJ, et al. (1985) Identification and typing of herpes simplex virus types 1 and 2 by monoclonal antibodies, sensitivity to the drug (E)-5-(2-bromovinyl)-2'-deoxyuridine, and restriction endonuclease analysis of viral DNA. J Med Virol 15: 215-222.
41. Peretti S, Shaw A, Blanchard J, Bohm R, Morrow G, et al. (2005) Immunomodulatory effects of HSV-2 infection on immature macaque dendritic cells modify innate and adaptive responses. Blood 106: 1305-1313.
42. York LJ, Giorgio DP, Mishkin EM (1995) Immunomodulatory effects of HSV2 glycoprotein D in HSV1 infected mice: implications for immunotherapy of recurrent HSV infection. Vaccine 13: 1706-1712.
43. Manickan E and Rouse BT (1995) Roles of different T-cell subsets in control of herpes simplex virus infection determined by using T-cell-deficient mouse-models. Journal of virology 69: 8178-8179.
44. Daheshia M, Feldman LT, Rouse BT (1998) Herpes simplex virus latency and the immune response. Curr Opin Microbiol 1: 430-435.
45. Schmid DS, Rouse BT (1992) The role of T cell immunity in control of herpes simplex virus. Curr Top Microbiol Immunol 179: 57-74.
46. Goel N, Mao H, Rong Q, Docherty JJ, Zimmerman D, et al. (2002) The ability of an HSV strain to initiate zosteriform spread correlates with its neuroinvasive disease potential. Arch Virol 147: 763-773.
47. Trinchieri G, Pflanz S, Kastelein RA (2003) The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19: 641-644.
48. WHO (2003) Factsheet 211: influenza. World Health Organization.
49. WHO (2008) Global influenza surveillance. World Health Organization.
50. Carrat F, Flahault A (2007) Influenza vaccine: the challenge of antigenic drift. Vaccine 25: 6852-6862.
51. Uger RA, Chan SM, Barber BH (1999) Covalent linkage to beta2-microglobulin enhances the MHC stability and antigenicity of suboptimal CTL epitopes. J Immunol 162: 6024-6028.
52. Deliyannis G, Jackson DC, Ede NJ, Zeng W, Hourdakis I, et al. (2002) Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol 76: 4212-4221.
53. Chen W, Anton LC, Bennink JR, Yewdell JW (2000) Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses. Immunity 12: 83-93.
54. Fan J, Liang X, Horton MS, Perry HC, Citron MP, et al. (2004) Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22: 2993-3003.
55. Mozdzanowska K, Feng J, Eid M, Kragol G, Cudic M, et al. (2003) Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. Vaccine 21: 2616-2626.
56. Reid AH, Fanning TG, Janczewski TA, McCall S, Taubenberger JK (2002) Characterization of the 1918 "Spanish" influenza virus matrix gene segment. J Virol 76: 10717-10723.
57. Feng J, Zhang M, Mozdzanowska K, Zharikova D, Hoff H, et al. (2006) Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virology Journal 3: 102.
58. Zhang M, Zharikova D, Mozdzanowska K, Otvos L and Gerhard W (2006) Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza A virus. Molecular immunology 43: 2195-2206.
59. Zharikova D, Mozdzanowska K, Feng J, Zhang M, Gerhard W (2005) Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 79: 6644-6654.
60. Prabhu N, Prabakaran M, Ho HT, Velumani S, Qiang J, et al. (2009) Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J Virol 83: 2553-2562.
61. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, et al. (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
62. Tan PT, Khan AM, August JT (2011) Highly conserved influenza A sequences as T cell epitopes-based vaccine targets to address the viral variability. Hum Vaccin 7: 402-409.
63. Sui J, Hwang WC, Perez S, Wei G and Aird D, et al. (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nature structural & molecular biology 16: 265-273.
64. Pleguezuelos O, Robinson S, Stoloff GA, Caparros-Wanderley W (2012) Synthetic Influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled Phase I trial. Vaccine 30: 4655-4660.
65. Frick JS, Grunebach F, Autenrieth IB (2010) Immunomodulation by semi-mature dendritic cells: a novel role of Toll-like receptors and interleukin-6. Int J Med Microbiol 300: 19-24.